Plasma microRNAs as novel biomarkers for patients with intraductal papillary mucinous neoplasms of the pancreas

Cancer Prevention Research

Volumn 8, Issue 9, 2015, Pages 826-834

  Permuth Wey, Jennifer ^a   Chen, Dung Tsa ^a   Fulp, William J ^a   Yoder, Sean J ^a   Zhang, Yonghong ^a   Georgeades, Christina ^a,b   Husain, Kazim ^a   Centeno, Barbara Ann ^a   Magliocco, Anthony M ^a   Coppola, Domenico ^a   Malafa, Mokenge ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 107; MICRORNA 1185 5P; MICRORNA 142 3P; MICRORNA 145 5P; MICRORNA 146A 5P; MICRORNA 148A 3P; MICRORNA 181 5P; MICRORNA 181A 5P; MICRORNA 191 5P; MICRORNA 199A 3P; MICRORNA 200A 3P; MICRORNA 20A 5P; MICRORNA 20B 5P; MICRORNA 22 3P; MICRORNA 23A 3P; MICRORNA 24 3P; MICRORNA 26A 5P; MICRORNA 27A 3P; MICRORNA 29C 3P; MICRORNA 337 5P; MICRORNA 33A 5P; MICRORNA 340 5P; MICRORNA 355 5P; MICRORNA 423 5P; MICRORNA 4454; MICRORNA 574 3P; MICRORNA 593 3P; MICRORNA 663B; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR MARKER;

AGED; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; FEMALE; GENE EXPRESSION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; PANCREAS TUMOR; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RNA ANALYSIS; AREA UNDER THE CURVE; BLOOD; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; DISEASE COURSE; FACTUAL DATABASE; GENETICS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDY; QUALITY CONTROL; RETROSPECTIVE STUDY;

AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; QUALITY CONTROL; RETROSPECTIVE STUDIES;

EID: 84941779074     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0094     Document Type: Article

References (47)

1. American Cancer Society. Cancer facts and figures 2014. Atlanta: American Cancer Society. 2014.
2. Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, et al. Precancer: a conceptual working definition - results of a Consensus Conference. Cancer Detect Prev 2006;30:387-94.
3. Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. Gastroenterol Clin North Am 2007;36:831-49.
4. Sachs T, Pratt WB, Callery MP, Vollmer CM Jr. The incidental asymptomatic pancreatic lesion: nuisance or threat? J Gastrointest Surg 2009;13:405-15.
5. Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle 2008;7:2485-92.
6. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007;13:1668-74.
7. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
8. Permuth-Wey J, Chen YA, Fisher K, McCarthy S, Qu X, Lloyd MC, et al. A genome-wide investigation of microRNA expression identifies biologicallymeaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas. PLoS ONE 2015;10:e0116869.
9. Matthaei H, Schulick RD, Hruban RH, Maitra A. Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 2011;8:141-50.
10. Lubezky N, Loewenstein S, Ben-Haim M, Brazowski E, Marmor S, Pasmanik-Chor M, et al. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery 2013;153:663-72.
11. Caponi S, Funel N, Frampton AE, Mosca F, Santarpia L, Van Der Velde AG, et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol 2013;24:734-41.
12. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids - The mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-77.
13. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013;19:3600-10.
14. Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol 2014;6:22-33.
15. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25.
16. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J 2011;17:528-36.
17. Adsay NV FN, Furukawa T, Hruban RH, Klimstra DS, Kloppel G, et al. Intraductal Papillary Mucinous Neoplasm of the Pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumors of the digestive system. Lyon: WHO Press; 2010. p. 304-313.
18. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 2013;59:S1-6.
19. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 2012;5:492-7.
20. Kirschner MB, Edelman JJ, Kao SC, Vallely MP, Van Zandwijk N, Reid G. The impact of hemolysis on cell-free microRNA biomarkers. Front Genet 2013;4:94.
21. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article3.
22. Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, et al. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 2011;103:1859-70.
23. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, et al. Proliferative genes dominate malignancy-risk gene signature in histologicallynormal breast tissue. Breast Cancer Res Treat 2010;119:335-46.
24. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 2011;17:6356-66.
25. Hopewell EL, Zhao W, Fulp WJ, Bronk CC, Lopez AS, Massengill M, et al. Lung tumor NF-kappaB signaling promotes T cell-mediated immune surveillance. J Clin Invest 2013;123:2509-22.
26. Tanaka M, Fernandez-Del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-97.
27. Vergoulis T, Vlachos IS, Alexiou P, Georgakilas G, Maragkakis M, Reczko M, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res 2012;40:D222-9.
28. Available From: http://www.genome.jp/kegg/.
29. Suryawanshi S, Vlad AM, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2013;19:1213-24.
30. Fourie NH, Peace RM, Abey SK, Sherwin LB, Rahim-Williams B, Smyser PA, et al. Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome. Exp Mol Pathol 2014;96:422-5.
31. Hu J, Wang Z, Liao BY, Yu L, Gao X, Lu S, et al. Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer 2014;135:1187-94.
32. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311:392-404.
33. Tang S, Bonaroti J, Unlu S, Liang X, Tang D, Zeh HJ, et al. Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas 2013;42:740-59.
34. Kapoor S. miR-145 and its influence on tumor growth in systemic malignancies. Eur J Cancer Prev 2014;23:233.
35. Gao L, Yang Y, Xu H, Liu R, Li D, Hong H, et al. miR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. Tumour Biol 2014;35:8309-18.
36. Hirata H, Hinoda Y, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, et al. Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer 2014;110:1645-54.
37. Zhou F, Wang W, Xing Y, Wang T, Xu X, Wang J. NF-kappaB target microRNAs and their target genes in TNFalpha-stimulated HeLa cells. Biochim Biophys Acta 2014;1839:344-54.
38. Wang J, Chen J, Chang P, Le Blanc A, Li D, Abbruzzesse JL, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res 2009;2:807-13.
39. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012;58:610-8.
40. Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226-37.
41. Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S, et al. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS ONE 2013;8:e58929.
42. Su Y, Ni Z, Wang G, Cui J, Wei C, Wang J, et al. Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol 2012;13:468-75.
43. Zhang DX, Dai YD, Yuan SX, Tao L. Prognostic factors in patients with pancreatic cancer. Exp Ther Med 2012;3:423-32.
44. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9.
45. Chin LJ, Slack FJ. A truth serum for cancer-microRNAs have major potential as cancer biomarkers. Cell Res 2008;18:983-4.
46. Berger F, Reiser MF. Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences? Theranostics 2013;3:943-52.
47. Neelakandan K, Babu P, Nair S. Emerging roles for modulation of micro-RNA signatures in cancer chemoprevention. Curr Cancer Drug Targets 2012;12:716-40.